This video is not available for purchase in your country.

Glivec leukaemia drug action

K003/2147

Rights Managed

  • {{ default.width }}x{{ default.height }}
  • {{ default.frame_rate }}
  • {{ default.size }}

This video is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY

Caption

Glivec leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Glivec (Imatinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Glivec, the first such tyrosine kinase inhibitor to be produced, is marketed by Novartis.

Release details

Model release not required. Property release not required.

Downloadable Master

  • Duration: 00:00:10.01
  • Audio: No
  • Format: Photo - JPEG

Original

  • Capture Format: QuickTime Animation
  • Codec: None
  • Interlaced: Yes
  • Frame Size: 1920 x 1080

Contact us if you require the original or other formats.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Calculate price
  • Add to board